This question tests knowledge of parenteral medication administration and clinical judgment in opioid side effects. The key assessment finding after administration is RR 8/min with decreased consciousness, indicating overdose. Reporting the low RR with LOC change immediately is critical as it requires intervention like naloxone, aligning with safe practice. Pain reduction is expected; mild itching or repositioning requests are minor. The decision-making principle is rapid recognition of respiratory depression. Safety guidelines include continuous monitoring post-opioid. A transferable strategy is to have emergency protocols accessible for opioid-related events.

This question tests knowledge of parenteral medication administration and clinical judgment in aminoglycoside monitoring. The key assessment finding after administration is elevated creatinine with low urine output, signaling nephrotoxicity. Reporting the creatinine 2.1 mg/dL with decreased output immediately is critical as gentamicin can cause renal damage, aligning with safe practice. Mild nausea or temperature decrease is less urgent; intact IV site is positive but not the issue. The decision-making principle is to monitor renal function serially. Safety guidelines include holding for rising creatinine. A transferable strategy is to trend labs and output during ototoxic/nephrotoxic therapies.

This question tests knowledge of parenteral medication administration and clinical judgment in monitoring anticoagulants. The key assessment finding after administration is BP 88/54 with dizziness and cool skin, suggesting hemorrhage. Reporting the low BP with symptoms immediately is critical as it indicates bleeding complication, aligning with safe practice. Small ecchymosis or burning is common; requesting ice is minor. The decision-making principle is to detect hemodynamic instability post-dose. Safety guidelines require vital sign monitoring after enoxaparin. A transferable strategy is to assess for bleeding signs like hypotension routinely after injections.

This question tests knowledge of parenteral medication administration and clinical judgment in monitoring rapid-acting insulin. The key assessment finding after administration is blood glucose of 49 mg/dL with irritability and sleepiness, indicating hypoglycemia. Reporting the low glucose with behavior change immediately is critical as it requires urgent treatment, aligning with safe practice. Requesting a snack or mild hunger is normal; a small bruise is minor and expected. The decision-making principle is to recognize post-administration hypoglycemia symptoms promptly. Safety guidelines include glucose checks after insulin. A transferable strategy is to educate on hypoglycemia signs and monitor closely after doses.